PEGylated insulin lispro compounds
US9050371B2 · kind B2 · utility
1Cited by
7References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 9, 2009 |
| Grant date | Jun 9, 2015 |
| Priority date | — |
| Expiry date | Jun 9, 2029 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K1/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the field of diabetes. More particularly, the invention relates to PEGylated insulin lispro compounds that are PEGylated with high molecular weight poly(ethylene glycol), are highly soluble at physiological pH, have an extended duration of action, and characterized by pharmacokinetic, pharmacodynamic, and/or activity peak-trough ratios of less than 2. The invention also relates to methods of providing such molecules, to pharmaceutical compositions containing them, and to their therapeutic uses.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.